Trial Profile
ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms ABSORB EXTEND
- Sponsors Abbott Vascular
- 30 Aug 2017 Results of five-year follow up study, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
- 17 Dec 2013 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov
- 17 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov